Evolution of dupilumab‐associated conjunctivitis in patients with atopic dermatitis after switching dupilumab to tralokinumab or Janus kinase inhibitors (RESO‐ADOC study)

Documenti analoghi

• Patient's Perspective on the Impact of Psoriasis on Their Quality of Life After 1 Year of Tildrakizumab Treatment: Despite Clinical Improvement, Persistence of a Potential Mental Cicatricial Memory of the Disease
  di: Ziad Reguiai, et al.
  Pubblicazione: (2025)
• Single‐centre experience with tralokinumab in dupilumab‐experienced and naïve patients with atopic dermatitis
  di: Claire Fossati, et al.
  Pubblicazione: (2024)
• Abrocitinib: 1‐Year Real‐Life Experience From the French OMCCI Registry
  di: Elisa Cinotti, et al.
  Pubblicazione: (2026)
• Association between atopic dermatitis burden and sociodemographic index with dupilumab and tralokinumab utilization across 50 countries
  di: Arbie Sofia P. Merilleno, et al.
  Pubblicazione: (2024)
• Drug survival of dupilumab, tralokinumab and upadacitinib in patients with atopic dermatitis: An international, real‐world comparative study
  di: Tiago Torres, et al.
  Pubblicazione: (2025)